Oxford Nanopore
Oxford Nanopore Technologies was founded in 2005 to develop an electronic, single molecule sensing system based on nanopore science. The company now has more than 250 employees from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialization. Oxford Nanopore's instruments — MinIon, PromethIon, and GridIon are adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule.
Oxford Nanopore Facts
Â
CEO: Gordon Sanghera
Website: www.nanoporetech.com
Ticker symbol: Privately held
Headquarters: Oxford, UK
Number of employees: 250+
Rockefeller Foundation Funds Global Pathogen Sequencing With $20M, Forms Collaborations
The funding and alliances mark the first step in the foundation's establishment of a pandemic prevention institute, which will collaborate with similar efforts elsewhere.
The project leaders hope that T2T-CHM13 will be used as a new linear reference genome while they are generating phased genomes for the Human Pangenome Reference Consortium.
The method was used to analyze two epigenetic modification types that were previously undetectable with Oxford Nanopore sequencing.
NIH, Genomics England Launch Large-Scale Human Genome Sequencing Studies Using Nanopore Technology
The research projects will use Oxford Nanopore Technologies' PromethIon 48 instrument to sequence genomes of patients with dementia and cancer, respectively.